Comprehensive clinical analysis of gastric-type endocervical adenocarcinoma: a real-world multicenter study

作者：Lele Chang, Yaxin Kang, Yanhong Zhuo, Jing Liu, Lele Zang, Li Li, Ling Lin, Chengzhi Jiang, Huaiwu Lu, Qin Xu · 发表于：Annals of Medicine · 年份：2025 · DOI：10.1080/07853890.2025.2584735 · 被引用次数：3 · 研究领域：Gastric Cancer Management and Outcomes、Endometrial and Cervical Cancer Treatments、Esophageal Cancer Research and Treatment

Background Gastric-type endocervical adenocarcinoma (G-EAC) is a rare malignancy, and its clinicopathological characteristics remain poorly defined. This study aimed to evaluate the real-world features, treatment patterns, and outcomes of patients with G-EAC.Methods Clinical data from 124 patients diagnosed with G-EAC between 2012 and 2024 across four tertiary hospitals in China were retrospectively analyzed. Clinicopathological features, therapeutic approaches, and survival outcomes were assessed. Overall survival (OS) was the primary endpoint. Kaplan–Meier and Cox regression analyses were performed to identify prognostic factors.Results The median diagnostic age was 55 years (range, 33–82). At presentation, 62.1% of patients had invasion or metastasis, most commonly lymphovascular (47.6%). Surgery was performed in 81.5% of cases, and 84.7% received chemotherapy, primarily platinum-based (81.5%). Radiotherapy was administered to 69.4%. The 1-, 3-, and 5-year OS rates were 78.6%, 54.8%, and 46.1%, respectively. Older age (≥65 years; HR, 4.71; 95% CI, 1.52–14.58; p = 0.0071) and advanced stage (p < 0.05) predicted poorer OS, while surgery (HR, 0.10; 95% CI, 0.02–0.43; p = 0.0019) and multiple chemotherapy cycles (p < 0.05) were independent protective factors.Conclusions G-EAC exhibits aggressive behavior and unfavorable prognosis, with a 5-year OS of 46.1%. Multimodal treatment, particularly surgery combined with chemotherapy, remains the cornerstone of management and may impr...